文献
J-GLOBAL ID:202202257838842542
整理番号:22A0330624
ヒドロキシ尿素またはペグ化インターフェロンアルファ-2aを受ける高リスク本態性血小板血症および真性赤血球増加症患者における症状負担および生活の質: MPN-RC111および112試験の事後解析【JST・京大機械翻訳】
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials
著者 (8件):
Mazza Gina L
(Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA)
,
Mead-Harvey Carolyn
(Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA)
,
Mascarenhas John
(The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA)
,
Yacoub Abdulraheem
(Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS, USA)
,
Kosiorek Heidi E
(Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA)
,
Hoffman Ronald
(The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA)
,
Dueck Amylou C
(Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA)
,
Mesa Ruben A
(Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA)
資料名:
Lancet Haematology
(Lancet Haematology)
巻:
9
号:
1
ページ:
e38-e48
発行年:
2022年
JST資料番号:
W3150A
ISSN:
2352-3026
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)